symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LUCD,1.22,0,44567,53345354,0,1.1-2.364,-0.02,Lucid Diagnostics Inc.,USD,0001799011,US54948X1090,54948X109,NASDAQ Global Market,NASDAQ,Medical Devices,https://www.luciddx.com,"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.",Dr. Lishan  Aklog M.D.,Healthcare,US,,212 949 4319,One Grand Central Place,New York,NY,10165,,0,https://financialmodelingprep.com/image-stock/LUCD.png,2021-10-14,False,False,True,False,False
